CASI Historical Balance Sheet

CASI Stock

USD 1.29 0.01 0.77%

Trend analysis of CASI Pharmaceuticals balance sheet accounts such as Total Assets of 49.2 M, Total Current Liabilities of 38.3 M or Total Stockholder Equity of 1.8 M provides information on CASI Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of CASI Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using CASI Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining CASI Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether CASI Pharmaceuticals is a good buy for the upcoming year.

CASI Pharmaceuticals Inventory

2.78 Million

Build AI portfolio with CASI Stock

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CASI Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more detail on how to invest in CASI Stock please use our How to Invest in CASI Pharmaceuticals guide.

About CASI Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of CASI Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. CASI Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of CASI Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which CASI currently owns. An asset can also be divided into two categories, current and non-current.

CASI Pharmaceuticals Balance Sheet Chart

As of now, CASI Pharmaceuticals' Net Debt is decreasing as compared to previous years. The CASI Pharmaceuticals' current Cash And Short Term Investments is estimated to increase to about 32.1 M, while Total Assets are projected to decrease to under 49.2 M.

Common Stock Shares Outstanding Total Assets Total Current Liabilities Property Plant And Equipment Net

Add Fundamental

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Total Assets

Total assets refers to the total amount of CASI Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in CASI Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on CASI Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of CASI Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Most accounts from CASI Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into CASI Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CASI Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more detail on how to invest in CASI Stock please use our How to Invest in CASI Pharmaceuticals guide.As of now, CASI Pharmaceuticals' Net Debt is decreasing as compared to previous years. The CASI Pharmaceuticals' current Cash And Short Term Investments is estimated to increase to about 32.1 M, while Total Assets are projected to decrease to under 49.2 M.

	2022	2023	2024	2025 (projected)
Total Current Liabilities	17.0M	16.7M	36.5M	38.3M
Total Assets	96.2M	75.3M	53.7M	49.2M

Total Current Liabilities Total Assets

CASI Pharmaceuticals balance sheet Correlations

	Common Stock Shares Outstanding	Total Assets	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Total Equity	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Short Long Term Debt Total	Other Current Liab	Non Currrent Assets Other	Net Receivables	Non Current Liabilities Total	Other Current Assets	Short Term Debt	Other Assets	Long Term Debt
Common Stock Shares Outstanding		0.73	0.86	0.38	0.88	-0.14	-0.86	0.79	0.39	0.59	0.56	1.0	0.73	0.88	0.95	0.73	0.12	0.67	0.84	0.68	0.85	0.48	-0.14	0.56	0.18	0.94
Total Assets	0.73		0.32	0.89	0.77	-0.7	-0.6	0.8	0.82	0.89	0.89	0.74	0.75	0.39	0.6	0.94	0.67	0.06	0.34	0.73	0.37	0.16	-0.04	-0.02	0.44	0.82
Total Current Liabilities	0.86	0.32		-0.07	0.67	0.28	-0.71	0.5	-0.02	0.22	0.15	0.85	0.42	0.91	0.88	0.34	-0.27	0.85	0.9	0.4	0.93	0.45	-0.07	0.85	-0.03	0.76
Total Stockholder Equity	0.38	0.89	-0.07		0.43	-0.91	-0.29	0.52	0.94	0.76	0.93	0.4	0.55	-0.05	0.19	0.86	0.82	-0.27	-0.05	0.5	-0.05	-0.18	0.04	-0.29	0.39	0.53
Property Plant And Equipment Net	0.88	0.77	0.67	0.43		-0.12	-0.7	0.88	0.29	0.82	0.45	0.86	0.66	0.75	0.89	0.62	0.28	0.41	0.72	0.89	0.79	0.52	-0.08	0.29	0.23	0.84
Net Debt	-0.14	-0.7	0.28	-0.91	-0.12		0.11	-0.26	-0.95	-0.51	-0.88	-0.16	-0.41	0.31	0.07	-0.74	-0.75	0.5	0.27	-0.24	0.29	0.46	-0.02	0.4	-0.34	-0.28
Retained Earnings	-0.86	-0.6	-0.71	-0.29	-0.7	0.11		-0.66	-0.33	-0.45	-0.47	-0.86	-0.88	-0.78	-0.79	-0.63	-0.09	-0.59	-0.63	-0.57	-0.67	-0.55	0.59	-0.47	-0.15	-0.76
Accounts Payable	0.79	0.8	0.5	0.52	0.88	-0.26	-0.66		0.43	0.79	0.55	0.79	0.69	0.62	0.8	0.69	0.39	0.34	0.56	0.74	0.55	0.41	-0.13	0.11	0.27	0.79
Cash	0.39	0.82	-0.02	0.94	0.29	-0.95	-0.33	0.43		0.57	0.97	0.42	0.57	-0.04	0.17	0.89	0.7	-0.22	-0.03	0.34	-0.06	-0.3	0.0	-0.19	0.34	0.52
Non Current Assets Total	0.59	0.89	0.22	0.76	0.82	-0.51	-0.45	0.79	0.57		0.65	0.59	0.6	0.32	0.53	0.68	0.74	-0.06	0.23	0.8	0.33	0.21	-0.05	-0.08	0.48	0.67
Cash And Short Term Investments	0.56	0.89	0.15	0.93	0.45	-0.88	-0.47	0.55	0.97	0.65		0.58	0.62	0.15	0.35	0.95	0.67	-0.05	0.14	0.43	0.12	-0.12	-0.03	-0.07	0.39	0.66
Common Stock Total Equity	1.0	0.74	0.85	0.4	0.86	-0.16	-0.86	0.79	0.42	0.59	0.58		0.73	0.87	0.94	0.75	0.14	0.66	0.83	0.66	0.84	0.47	-0.13	0.56	0.21	0.94
Other Stockholder Equity	0.73	0.75	0.42	0.55	0.66	-0.41	-0.88	0.69	0.57	0.6	0.62	0.73		0.53	0.62	0.76	0.35	0.28	0.41	0.64	0.43	0.41	-0.53	0.12	0.24	0.69
Total Liab	0.88	0.39	0.91	-0.05	0.75	0.31	-0.78	0.62	-0.04	0.32	0.15	0.87	0.53		0.92	0.38	-0.23	0.86	0.91	0.5	0.92	0.73	-0.14	0.66	0.09	0.76
Property Plant And Equipment Gross	0.95	0.6	0.88	0.19	0.89	0.07	-0.79	0.8	0.17	0.53	0.35	0.94	0.62	0.92		0.57	-0.07	0.7	0.9	0.64	0.93	0.61	-0.07	0.54	0.17	0.89
Total Current Assets	0.73	0.94	0.34	0.86	0.62	-0.74	-0.63	0.69	0.89	0.68	0.95	0.75	0.76	0.38	0.57		0.52	0.15	0.39	0.57	0.35	0.11	-0.03	0.03	0.34	0.81
Common Stock	0.12	0.67	-0.27	0.82	0.28	-0.75	-0.09	0.39	0.7	0.74	0.67	0.14	0.35	-0.23	-0.07	0.52		-0.42	-0.37	0.39	-0.3	-0.28	-0.11	-0.32	0.48	0.21
Short Long Term Debt Total	0.67	0.06	0.85	-0.27	0.41	0.5	-0.59	0.34	-0.22	-0.06	-0.05	0.66	0.28	0.86	0.7	0.15	-0.42		0.78	0.15	0.73	0.59	-0.08	0.79	-0.14	0.54
Other Current Liab	0.84	0.34	0.9	-0.05	0.72	0.27	-0.63	0.56	-0.03	0.23	0.14	0.83	0.41	0.91	0.9	0.39	-0.37	0.78		0.54	0.96	0.58	0.08	0.6	-0.12	0.72
Non Currrent Assets Other	0.68	0.73	0.4	0.5	0.89	-0.24	-0.57	0.74	0.34	0.8	0.43	0.66	0.64	0.5	0.64	0.57	0.39	0.15	0.54		0.57	0.39	-0.12	0.01	0.0	0.62
Net Receivables	0.85	0.37	0.93	-0.05	0.79	0.29	-0.67	0.55	-0.06	0.33	0.12	0.84	0.43	0.92	0.93	0.35	-0.3	0.73	0.96	0.57		0.59	0.0	0.67	0.01	0.75
Non Current Liabilities Total	0.48	0.16	0.45	-0.18	0.52	0.46	-0.55	0.41	-0.3	0.21	-0.12	0.47	0.41	0.73	0.61	0.11	-0.28	0.59	0.58	0.39	0.59		-0.29	0.18	0.17	0.37
Other Current Assets	-0.14	-0.04	-0.07	0.04	-0.08	-0.02	0.59	-0.13	0.0	-0.05	-0.03	-0.13	-0.53	-0.14	-0.07	-0.03	-0.11	-0.08	0.08	-0.12	0.0	-0.29		-0.09	-0.07	0.03
Short Term Debt	0.56	-0.02	0.85	-0.29	0.29	0.4	-0.47	0.11	-0.19	-0.08	-0.07	0.56	0.12	0.66	0.54	0.03	-0.32	0.79	0.6	0.01	0.67	0.18	-0.09		-0.07	0.45
Other Assets	0.18	0.44	-0.03	0.39	0.23	-0.34	-0.15	0.27	0.34	0.48	0.39	0.21	0.24	0.09	0.17	0.34	0.48	-0.14	-0.12	0.0	0.01	0.17	-0.07	-0.07		0.25
Long Term Debt	0.94	0.82	0.76	0.53	0.84	-0.28	-0.76	0.79	0.52	0.67	0.66	0.94	0.69	0.76	0.89	0.81	0.21	0.54	0.72	0.62	0.75	0.37	0.03	0.45	0.25

Click cells to compare fundamentals

CASI Pharmaceuticals Account Relationship Matchups

CASI Pharmaceuticals balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Common Stock Shares Outstanding	11.0M	13.6M	13.6M	13.4M	15.3M	16.1M
Total Assets	127.7M	138.3M	96.2M	75.3M	53.7M	49.2M
Total Current Liabilities	8.0M	13.2M	17.0M	16.7M	36.5M	38.3M
Total Stockholder Equity	81.5M	84.5M	44.6M	24.2M	1.9M	1.8M
Property Plant And Equipment Net	10.8M	21.8M	13.2M	11.6M	11.4M	11.9M
Net Debt	(55.8M)	(36.5M)	(45.8M)	4.2M	8.7M	9.1M
Retained Earnings	(570.5M)	(605.6M)	(637.2M)	(660.8M)	(700.1M)	(665.1M)
Accounts Payable	3.7M	4.8M	3.3M	4.4M	2.7M	2.7M
Cash	57.1M	38.7M	47.1M	17.1M	13.5M	12.8M
Non Current Assets Total	53.7M	76.3M	22.8M	15.9M	13.9M	9.9M
Cash And Short Term Investments	66.4M	48.6M	51.3M	30.8M	16.1M	32.1M
Common Stock Total Equity	953.7K	979K	1.2M	1.4M	1.6M	1.7M
Liabilities And Stockholders Equity	127.7M	138.3M	96.2M	75.3M	53.7M	49.2M
Other Stockholder Equity	650.2M	686.8M	682.4M	686.2M	703.7M	396.2M
Total Liab	24.2M	30.3M	29.3M	51.1M	51.8M	54.4M
Property Plant And Equipment Gross	10.8M	12.7M	15.5M	16.3M	17.1M	17.9M
Total Current Assets	74.0M	62.0M	73.4M	59.3M	39.6M	39.3M
Accumulated Other Comprehensive Income	589K	2.0M	(703K)	(1.2M)	(1.8M)	(1.9M)
Common Stock	979K	1.2M	1.4M	1K	2K	1.9K
Short Long Term Debt Total	1.3M	2.2M	1.3M	21.2M	22.1M	23.2M
Other Current Liab	1.6M	6.7M	10.8M	11.1M	11.6M	12.2M
Non Currrent Assets Other	299K	2.2M	1.1M	766K	587K	331.0K
Net Receivables	4.6M	9.8M	13.0M	10.1M	15.3M	16.1M
Non Current Liabilities Total	16.2M	17.2M	12.3M	34.4M	15.4M	16.1M
Other Current Assets	1.7M	1.7M	3.0M	2.6M	2.9M	2.3M
Short Term Debt	2.2M	1.1M	868K	728K	19.6M	20.6M
Other Assets	504K	38.4M	2.2M	197K	226.6K	215.2K
Property Plant Equipment	1.8M	985K	10.8M	22.0M	25.3M	26.6M
Short Term Investments	9.3M	9.9M	4.2M	13.7M	2.6M	4.8M
Inventory	1.4M	1.9M	6.1M	15.9M	5.3M	2.8M
Intangible Assets	13.2M	12.2M	1.1M	1.8M	238K	226.1K
Net Tangible Assets	109.5M	93.7M	68.3M	72.3M	83.1M	50.3M

Currently Active Assets on Macroaxis

USOI	Credit Suisse X Links
ULTY	Tidal Trust II
CONY	YieldMax N Option
BCAT	BlackRock Capital Allocation
PDI	Pimco Dynamic Income

When determining whether CASI Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CASI Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Casi Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Casi Pharmaceuticals Stock:

How To Invest In CASI

Details

Is CASI Stock a good investment?

Details

What is CASI Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more detail on how to invest in CASI Stock please use our How to Invest in CASI Pharmaceuticals guide.

You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CASI Pharmaceuticals. If investors know CASI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CASI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.54)

Revenue Per Share

1.977

Quarterly Revenue Growth

0.83

Return On Assets

(0.51)

Return On Equity

(10.95)

The market value of CASI Pharmaceuticals is measured differently than its book value, which is the value of CASI that is recorded on the company's balance sheet. Investors also form their own opinion of CASI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is CASI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CASI Pharmaceuticals' market value can be influenced by many factors that don't directly affect CASI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between CASI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if CASI Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CASI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

CASI Historical Balance Sheet

CASI Pharmaceuticals Inventory

2.78 Million

About CASI Balance Sheet Analysis

CASI Pharmaceuticals Balance Sheet Chart

Common Stock Shares Outstanding

Total Assets

Total Current Liabilities

Property Plant And Equipment Net

CASI Pharmaceuticals balance sheet Correlations

CASI Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

CASI Pharmaceuticals balance sheet Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock Total Equity	+ 1.0	Common Stock Shares Outstanding
Cash And Short Term Investments	+ 0.97	Cash
Net Receivables	+ 0.96	Other Current Liab
Property Plant And Equipment Gross	+ 0.95	Common Stock Shares Outstanding
Total Current Assets	+ 0.95	Cash And Short Term Investments
Long Term Debt	+ 0.94	Common Stock Shares Outstanding

Cash	- 0.95	Net Debt
Net Debt	- 0.91	Total Stockholder Equity
Other Stockholder Equity	- 0.88	Retained Earnings
Cash And Short Term Investments	- 0.88	Net Debt
Common Stock Total Equity	- 0.86	Retained Earnings
Retained Earnings	- 0.86	Common Stock Shares Outstanding